Temozolomide and Cisplatin in relapsed/refractory acute leukemia

Journal of Hematology and Oncology

Volumn 2, Issue , 2009, Pages

  Seiter, Karen ^a   Srekatragadda, Edhar ^a   Ponce, Doris ^a   Rasul, Muhammad ^a   Ahmed, Nasir ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CISPLATIN; HYDROXYUREA; MAGNESIUM; POTASSIUM; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE;

ACUTE BIPHENOTYPIC LEUKEMIA; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BLOOD TRANSFUSION; BONE MARROW CELL; BRADYCARDIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONSTIPATION; CREATININE BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FLUID THERAPY; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PHASE 1 CLINICAL TRIAL; REFRACTORY ACUTE LEUKEMIA; SAFE SEX; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; DRUG EFFECT; DRUG RESISTANCE; MIDDLE AGED; RECURRENT DISEASE; SALVAGE THERAPY; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; SALVAGE THERAPY; TREATMENT FAILURE; YOUNG ADULT;

EID: 67651162337     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-2-21     Document Type: Article

References (21)

1. Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E: Potential cure of acute myeloid leukemia: analysis of 1069 consecutive patients in first complete remission. Cancer 2007, 110:2756-2760.
2. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, Lazarus HM, Franklin IM, Litzow MR, Ciobanu N, Prentice HG, Durrant J, Tallman MS, Goldstone AH, ECOG, MRC/NCRI Adult Leukemia Working Party: Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005, 106:3760-3767.
3. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA: Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5, 1-d]-1, 2, 3, 5-tetrazin-4 (3H) -one (CCRG 81045; M & B 39381), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987, 47:5846-5852.
4. Tentori L, Graziani G, Gilberti S, Lacal PM, Bonmassar E, D'Atri S: Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines. Leukemia 1995, 9:1888-1895.
5. Seiter K, Liu D, Loughran T, Siddiqui A, Baskind P, Ahmed T: Phase I study of temozolomide in relapsed/refractory acute leukemia. J Clin Oncol 2002, 20:3249-3253.
6. Bobola MS, Tseng SH, Blank A, Berger MS, Silber JR: Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin Cancer Res 1996, 2:735-741.
7. Wang G, Weiss C, Sheng P, Bresnick E: Retrovirus-mediated transfer of the human O6-methylguanine-DNA methyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents. Biochem Pharmacol 1996, 51:1221-1228.
8. Taverna P, Catapano CV, Citti L, Bonfanti M, D'Incalci M: Influence of O6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas. Anticancer Drugs 1992, 3:401-405.
9. Lacal PM, D'Atri S, Orlando L, Bonmassar E, Graziani G: In vitro inactivation of human O6-alkylguanine DNA alkyltransferase by antitumor triazene compounds. J Pharmacol Exp Ther 1996, 279:416-422.
10. Friedman HS, Johnson SP, Dong Q, Schold SC, Rasheed BK, Bigner SH, Ali-Osman F, Dolan E, Colvin OM, Houghton P, Germain G, Drummond JT, Keir S, Marcelli S, Bigner DD, Modrich P: Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res 1997, 57:2933-2936.
11. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Zambruno G, Bonmassar E, Jiricny J: Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 1998, 54:334-341.
12. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
13. D'Atri S, Piccioni D, Castellano A, Tuorto V, Franchi A, Lu K, Christiansen N, Frankel S, Rustum YM, Papa G: Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukemic patients. Ann Oncol 1995, 6:389-393.
14. Piccioni D, D'Atri S, Papa G, Caravita T, Franchi A, Bonmassar E, Graziani G: Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. J Chemother 1995, 7:224-229.
15. 6 -methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in Jurkat cells. J Pharmacol Exp Ther 2000, 294:664-671.
16. Estey E: Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 2000, 14:476-479.
17. Giles F, O'Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H: Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer 2005, 104:547-554.
18. Gale GR, Walker EM Jr, Atkins LM, Smith AB, Meischen SJ: Res Commun Chem Pathol Pharmacol: Antileukemic properties of dichloro (1, 2-diaminocyclohexane) platinum (II). Res Commun Chem Pathol Pharmacol 1974, 7:529-538.
19. Welborn JL, Kopecky KJ, Meyers FJ, Veith R, Shurafa M, Doroshow JH, Balcerzak SP, Appelbaum FR: Carboplatin infusion in relapsed and refractory acute myeloid leukemia - a Southwest Oncology Group trial. Leukemia 1995, 9:1126-1129.
20. Brandwein JM, Yang L, Schimmer AD, Schuh AC, Gupta V, Wells RA, Alibhai SM, Xu W, Minden MD: A phase II study of temozolomide therapy for poor-risk patients aged > or = 60 years with acute myeloid leukemia: low levels of MGMT predict for response. Leukemia 2007, 21:821-824.
21. Caporaso P, Turriziani M, Venditti A, Marchesi F, Buccisano F, Tirindilli MC, Alvino E, Garbin A, Tortorelli G, Toppo L, Bonmassar E, D'Atri S, Amadori S: Novel role of triazines in haematological malignancies: pilot study of temozolomide, lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukemia. DNA Repair 2007, 6:1179-1186.